Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma
NCT01335074Phase 2Withdrawn
- Sponsor
- Philipps-Universität Marburg
- Start
- Apr 2011
- Primary completion
- Dec 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of temsirolimus in hepatocellular carcinoma (HCC), sponsored by Philipps-Universität Marburg. Planned start Apr 2011; status: withdrawn.
02
Drugs
temsirolimus
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT01335074.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01335074.